Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen with minimal to no titration necessary ...
Introduction & Objectives Idiopathic arterial pulmonary hypertension (IPAH) is a chronic, progressive respiratory disease, characterised by elevated pulmonary artery pressure. The disease carries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results